Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Ruxolitinib add-on therapy in...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience

Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience

Bibliographic Details
Main Authors: Yi-Lun Wang, Tsung-Yen Chang, Yu-Chuan Wen, Shu-Ho Yang, Yi-Wen Hsiao, Shih-Hsiang Chen, Tang-Her Jaing
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Pediatrics and Neonatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1875957223001997
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S1875957223001997

Similar Items

  • Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
    by: Enrico Maffini, et al.
    Published: (2016-08-01)
  • Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
    by: Shuang Fan, et al.
    Published: (2022-08-01)
  • Management of pediatric steroid-refractory graft versus host disease: Challenges and outcome with ruxolitinib and etanercept
    by: Sanjana Sarangarajan, et al.
    Published: (2024-01-01)
  • Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
    by: Dong Wang, et al.
    Published: (2021-06-01)
  • Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
    by: Wei C, et al.
    Published: (2021-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs